<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572932</url>
  </required_header>
  <id_info>
    <org_study_id>Irritable Bowel Syndrome</org_study_id>
    <nct_id>NCT04572932</nct_id>
  </id_info>
  <brief_title>Probiotics and Irritable Bowel Syndrome</brief_title>
  <official_title>Evaluation of the Use of Probiotics In Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial was conducted on 90 IBS patients, who fulfill ROME IV criteria and the&#xD;
      IBS diagnostic questionnaire (Arabic version licensed by Rome Foundation) in Egyptair&#xD;
      hospital outpatient clinic, Cairo, Egypt between May and December 2019. Data of the patient,&#xD;
      with suspected IBS during the study period, were reviewed and the patients who fulfilled the&#xD;
      inclusion criteria were enrolled into this study. A written consent was obtained from all&#xD;
      included patients. The patients who agreed to participate were then randomly assigned into&#xD;
      two equal groups and were followed up after 4 weeks from the first visit.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study includes 90 patients assigned into2 equal groups the first was prescribed&#xD;
      probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and&#xD;
      itopride hcl 50mg three times daily, while the second group receivedonly itopridehcl 50mg by&#xD;
      the same dose for four weeks.All patients fulfill ROME IV criteria and the IBS diagnostic&#xD;
      questionnaire (Arabic version licensed by Rome Foundation). Data of the patient, with&#xD;
      suspected IBS during the study period, were reviewed and the patients who fulfilled the&#xD;
      inclusion criteria were enrolled into this study. A written consent was obtained from all&#xD;
      included patients. The patients who agreed to participate were then randomly assigned into&#xD;
      two equal groups and were followed up after 4 weeks from the first visit.&#xD;
&#xD;
      Any patient with red flags (e.g. weight or appetite loss, iron deficiency anemia, fever or&#xD;
      rectal bleeding), Known inflammatory bowel disease or celiac disease patients, patients above&#xD;
      50 years of age and immuno-compromised patients were excluded from the study.&#xD;
&#xD;
      The included patients aged from 18 to 50 years fulfilling Rome IV criteria for diagnosis of&#xD;
      IBS:Recurrent abdominal pain (on average, at least 1 day/week in the last 3 months)&#xD;
      associated with two or more of the following: (Related to defecation, Associated with a&#xD;
      change in frequency of stool, Associated with a change in form of stool).Patients should&#xD;
      fulfill Rome Foundation IBS-Diagnostic Questionnaire.&#xD;
&#xD;
      All patients were subjected to initial evaluation byfull history taking, questionnaires for&#xD;
      (IBS diagnostic questionnaire, IBS-SSSand QOL -IBS survey), clinical examination,&#xD;
      investigations (including CBC, ESR, CRP, random sugar, HbA1c, thyroid profile and stool&#xD;
      analysis) and radiological assessment bypelvi-abdominal ultrasound to exclude any organic&#xD;
      cause..Group one(45 patients) was prescribed probiotic (lactobacillus delbruekii and l.&#xD;
      fermentum) 10billion colony forming units and itopride 50mg three times daily for four weeks&#xD;
      while group two was prescribed only itopride 50mg three times daily for four weeks.Then&#xD;
      reassessment of the questionnaires was done after 4 weeks of treatment for comparison&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of IBS Symptoms</measure>
    <time_frame>4 weeks</time_frame>
    <description>via Irritable bowel syndrom severity scale (IBS-SSS Arabic version)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>group 1:Probiotic arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>first group was prescribed probiotics (10 billion colony of lactobacillus delbruekii and lactobacillus fermentum) and itopride hcl 50mg three times daily for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:Placcebo arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the second group received only itopridehcl 50mg by the same dose for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactobacillus delbruekii</intervention_name>
    <description>Comarsion between probiotics and one of the most widely used symptomatc treatment for IBS itopride hcl</description>
    <arm_group_label>Group 2:Placcebo arm</arm_group_label>
    <arm_group_label>group 1:Probiotic arm</arm_group_label>
    <other_name>and lactobacillus fermentum)</other_name>
    <other_name>and itopride hcl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1-Patients should fulfill Rome Foundation IBS-Diagnostic Questionnaire i.e [Recurrent&#xD;
        abdominal pain (on average, at least 1 day/week in the last 3 months) associated with two&#xD;
        or more of the following: (Related to defecation, Associated with a change in frequency of&#xD;
        stool, Associated with a change in form of stool)].&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any patient with red flags (e.g. weight or appetite loss, iron deficiency anemia,&#xD;
             fever or rectal bleeding),&#xD;
&#xD;
          2. Known inflammatory bowel disease or celiac disease patients,&#xD;
&#xD;
          3. patients above 50 years of age&#xD;
&#xD;
          4. immuno-compromised patients&#xD;
&#xD;
          5. Refusal to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tropical medicine department</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 27, 2020</study_first_submitted>
  <study_first_submitted_qc>September 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>October 1, 2020</last_update_submitted>
  <last_update_submitted_qc>October 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Iman Fawzy Montasser</investigator_full_name>
    <investigator_title>Associate Professor of Tropical Medicine</investigator_title>
  </responsible_party>
  <keyword>intestinal microbiota,</keyword>
  <keyword>probiotics,</keyword>
  <keyword>quality of life,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>To publish the results of this research . further studies on larger number of patients and for longer durtion as future plan</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

